Enhancing Renewable Energy Adoption in Rural Communities: A Comprehensive Study

Jan 12, 2025

10 likes | 73 Views

This study by Uppalapati et al. provides insights into strategies to promote renewable energy use in rural areas. It analyzes challenges, opportunities, and solutions for sustainable energy transitions in remote communities.

Share Presentation

Embed Code

dareh

Download Presentation

Enhancing Renewable Energy Adoption in Rural Communities: A Comprehensive Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Uppalapati et al., Supplementary Figure 4 (revised)

Supplementary Figure 4 Hori et al.

One-dimensional gel electrophoresis (SDS-PAGE)

107 views • 1 slides

Supplementary Figure 7 Hori et al.

A. ~70. 75. ~65. 50. 5-20% ePAGEL (Anti-phospho (T514) CRMP2 antibody). B. 75. ~70. 50. 5-20% ePAGEL (Anti-phospho (S522) CRMP2 antibody). Western blot analysis of the anti-phosphorylated CRMP2 proteins cross-reacting proteins

166 views • 1 slides

Desjardins, et. al., Supplementary Figure 4

Desjardins, et. al., Supplementary Figure 4. *.

74 views • 1 slides

Thiruchelvam et al Supplementary Figure 4

A. B. C. D. Thiruchelvam et al Supplementary Figure 4.

76 views • 1 slides

Mertens et al., Supplementary Figure

Mertens et al., Supplementary Figure.

68 views • 1 slides

Uppalapati et al. , Supplementary Figure 3

Uppalapati et al. , Supplementary Figure 3.

76 views • 1 slides

Supplementary Figure S1 Wang et. al.

Supplementary Figure S1 Wang et. al. Pre-sort. Post-sort. a. 10 5. 4.12. 0.07. 10 4. WT. 10 3. 10 2. 0. 10 5. 5.47. 0.16. 10 4. Bim /. 10 3. 10 2. CD25. 0. 0. 10 2. 10 3. 10 4. 10 5. 0. 10 2. 10 3. 10 4. 10 5. Foxp3. b. Bim /. WT. 10 5. 10 4. 10 3. 10 2.

132 views • 4 slides

Supplementary Figure 1 Lewis, et al.

Cell Death (Ramos). Untreated. Proliferation (Ramos). hIgG (crosslinked). Dacetuzumab (soluble). Dacetuzumab (crosslinked). Percent Cell Death (apoptotic + necrotic). Crosslinking Ab. Dacetuzumab (soluble). hIgG (crosslinked). Dacetuzumab (crosslinked). CD40 Ligand.

103 views • 1 slides

Nakayama et al. , Supplementary Figure 3

Nakayama et al. , Supplementary Figure 3. HNF4G/ACTB (microarray). HNF4G/ACTB (qRT-PCR). 0.035. 2.0. 0.030. 1.5. 0.025. 0.020. 1.0. 0.015. 0.010. 0.5. 0.005. 0.000. 0.0. SS043. SS043. SS043. SS043. SS043. SS043. SS046. SS046. SS046. SS046. SS046. SS046. SS049. SS049.

71 views • 1 slides

Farmer et al Supplementary Figure 1

Farmer et al Supplementary Figure 1. [ KU0058684] (  M). 1. 2. 0. 1. 0. 0. IC 50 = 1nM. 0.00001. 0.0001. KU0051529 PARP-1 IC 50 = 730nM. 0.001. 0.01. 8. 0. 0.1. 100. 10. 0. 1. % activity. 6. 0. 4. 0. 2. 0. 0. 10 -6. 10 -5. 10 -4. 10 -3. 10 -2. 10 -1. 10 0.

214 views • 7 slides

Supplementary Figure 1. Suzuki et al.

BrdU. DAPI/BrdU. 24 hrs. 24 hrs. 48 hrs. 48 hrs. 72 hrs. 72 hrs. Supplementary Figure 1. Suzuki et al. A. B. Supplementary Figure 2. Suzuki et al. p. CPD. H2AX. Merge. p. (6-4) photo. H2AX. Merge. p. XRCC1. H2AX. Merge. Supplementary Figure 3. Suzuki et al. No UV. 3 min.

192 views • 8 slides

Yoon et al. Supplementary Figure S4

Yoon et al. Supplementary Figure S4. A. B. AGS. MKN-45. N87. AGS. MKN-45. N87. Monolayer. Monolayer. Spheroid/ Scr.shRNA. Spheroid/ DMSO. Spheroid/ Smo.shRNA. Spheroid/ Vismodegib. C. AGS. MKN-45. N87. Monolayer. Spheroid/ DMSO. Spheroid/ Vismodegib. 50 μ m.

113 views • 1 slides

Supplementary Figure 1 Logan et al

IP Ab. HSF1. we. Irr. p63. HSF1 Int. I. II. III. IV. V. F/l.  Pro. 1-292. 248-393. 1-42. TAD DBD Oligo. +. +. 248-393. 1-42. 1-292.  Pro. GST. Inputs. F/l. +. -. -. Pull down. Supplementary Figure 1 Logan et al.

113 views • 4 slides

Supplementary Figure S1, Schneider et al

Supplementary Figure S1, Schneider et al. Fully migrated out of seeded (FM ratio). A. medium. WT sup. total PBMC. NS. KO sup. medium. NS. NS. NS. NS. WT sup. lymphocytes. NS. KO sup. medium. monocytes. WT sup. NS. KO sup. 0. 10. 20. 30. 40. 50. FM ratio (%).

128 views • 1 slides

Yang et al. Supplementary Figure S1

pAWF-DIAP1. CG7023. CG5384. CG5603. CG7288. CG12082. CG8830. CG5798. CG5505. CG8494. CG4165. CG30421. CG3781. CG4968. CG9448. CG14884. vec. pAMW. 150. 150. 100. 100. 75. 75. 50. 50. FLAG (DIAP1). 37. 37. 25. 25. 20. 20. Actin. Yang et al. Supplementary Figure S1.

103 views • 1 slides

Oiva et al., Supplementary Figure.

Oiva et al., Supplementary Figure. P < 0.0001. 1000. P < 0.0001. 100. Trypsinogen-3 (  g/L). 10. 1. 0.1. Mild AP. Severe AP. Controls.

145 views • 1 slides

Supplementary Figure 5. Nikolova et al

Supplementary Figure 5. Nikolova et al.

87 views • 1 slides

Gentile et al., Supplementary Figure 4

HGF 1h. HGF 6h. HGF 24h. 1. 0.5. 0. -0.5. -1. -1.5. -2. -2.5. -3. Abr. Bcr. Chn2. Sh3bp1. Arhgap5. Arhgap9. Arhgap1. Racgap1. Arhgap29. Arhgap12. Log2 Ratio. Gentile et al., Supplementary Figure 4

119 views • 1 slides

Supplementary Figure 1_Van Looy et al.

76 views • 1 slides

Sansone et al, Supplementary Figure 2

HYPO-7. A. 1 MONTH 6 MONTHS 1 YEAR. B. c. 1 MONTH 6 MONTHS 1 YEAR. HYPO-7. MCF-7 + - + - + - HYPO-7 - + - + - +. DFX 600 m M - +. CA-IX.

248 views • 1 slides

Gentile et al., Supplementary Figure 6

A. B. C. Cell Density (Arbitrary Units). D. Cell Density (Arbitrary Units). Gentile et al., Supplementary Figure 6

108 views • 1 slides

Supplementary figure 1 Palacios et. al

E-cadherin. Transferrin. Merge. 35 °C/ 4hrs. Supplementary figure 1 Palacios et. al. 0 4 8 12 0 4 8 12. Hours of v-Src activation. Extracellular domain epitope Cytoplasmic domain epitope. { Anti-E-cadherin. Supplementary figure 2

94 views • 2 slides

More Related